Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis #ActAgainstAmputation @usc_vascular

Here are the most up-to-date data on the possible association (or not) of SGLT2 inhibitors to diabetes related lower extremity amputation

Conclusions: Overall, there was no consistent evidence of SGLT2i exposure and increased risk of amputation. The increased risk of amputation seen in the large, long-term Canagliflozin Cardiovascular Assessment Study (CANVAS) trial for canagliflozin, and select observational studies, merits continued exploration.

David G. Armstrong

Dedicated to amputation prevention, wound healing, diabetic foot, biotechnology and the intersection between medical devices and consumer electronics.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.